Using genetic testing to guide schizophrenia medication choices
Part of Mental health clinical trials.
This trial tests whether a genetic test (pharmacogenomics) can help doctors choose better medications for people with schizophrenia. If you've had side effects or your symptoms haven't improved with your current antipsychotic, this study may help find a treatment that works better for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a schizophrenia diagnosis (confirmed by a doctor).
- You are between 18 and 65 years old.
- You are currently receiving psychiatric care, either as an inpatient or at an outpatient clinic.
- You have had problems with your current antipsychotic medication: either side effects that required a change, or symptoms that stayed high after 4+ weeks of treatment, or your doctor deciding a change is needed.
- You are able to understand the study and give written permission (informed consent) to join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether using brain scans and genetic tests can help choose the best treatment for people early in their schizophrenia. It will check if these biomarkers can predict who will respond better to medication.
This study looks at how a person's genes may affect how their body processes antipsychotic medications, with the goal of helping doctors choose the best medication and dose for each person. If you are changing or starting a new antipsychotic, this study might help you get more personalized treatment.
This study tests if using genetic information can help doctors choose the right mental health medication or dose. It may help find treatments that work better with fewer side effects.
This study compares a personalized medication plan based on your genes versus standard dosing for people with depression, anxiety, or psychosis. It may help your clinician choose a safer or more effective dose or medicine by using pharmacogenomics (gene-informed prescribing).
This study looks at brain chemicals involved in “glutamate” and “GABA” signaling in people with schizophrenia (and separately in healthy volunteers). It may help researchers understand what’s going wrong in the brain and guide future treatments.
This study tests whether using a genetic test can help doctors choose the most effective antidepressant for people with depression. The goal is to improve treatment outcomes and reduce side effects by tailoring the medication to your genetic makeup.
Hear when a new Schizophenia Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.